Back to today’s briefing

Story perspectives

Novo Nordisk Ends Partnership, Hims & Hers Shares Plunge 35%

6/26/2025

23 4

Summary

Story summary

Novo Nordisk has cut ties with telehealth firm Hims & Hers, citing misleading marketing and the sale of unauthorized compounded versions of Wegovy, its weight-loss drug. This partnership, which started in April, unraveled over compliance issues, leading to a staggering 35% drop in Hims & Hers shares and a 5% decline for Novo amid growing regulatory scrutiny.

1 of 1

Story summary

Novo Nordisk has cut ties with telehealth firm Hims & Hers, citing misleading marketing and the sale of unauthorized compounded versions of Wegovy, its weight-loss drug. This partnership, which started in April, unraveled over compliance issues, leading to a staggering 35% drop in Hims & Hers shares and a 5% decline for Novo amid growing regulatory scrutiny.